Skip to content

Inspection Record

Sanofi Pasteur — FDA 483 Findings

US FDAInspected 2023-09-29Published 2026-10-26 5 findingsAseptic processing and sterility assuranceDocumentation and recordsOther quality systemComplaint and recall handlingLaboratory and QC controls

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not followed.

2Documentation and records

The master production and control records are deficient in that they do not include complete instructions, Specifically, there are no defined (1) (4)time frames and/or instructions for the (Bb) (4) preparation ofthe Concentrated Tetanus Protein (CTP) bulk in the Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) manufacturing process.

3Other quality system

Drug products are not stored under appropriate conditions so that their identity, strength, quality, and purity are not affected.

4Complaint and recall handling

were observed to contain cellulose particles during visual inspection of retain samples related to @ complaint of vial breakage (complaint no.

5Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Sanofi Pasteur findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.